#Sweden #MedTech #Stockholm #Implantica #RefluxStop

Implantica Hosts Capital Markets Day in Stockholm

Event Date: September 9, 2026
Time: 14:00 - 16:30 CEST
Location: Sergelkonferensen, Mäster Samuelsgatan 42, Stockholm

Implantica AG, a pioneering medtech firm known for its advanced implantable technologies, has announced the upcoming Capital Markets Day scheduled for September 9, 2026, in Stockholm. This pivotal event will spotlight the U.S. launch of their innovative product, RefluxStop®, which has recently gained FDA approval. Peter Forsell, CEO and founder of Implantica, emphasized the significance of this moment, describing it as a major opportunity for the company as it enters the largest global market for medical technologies.

RefluxStop®, designed for the treatment of gastroesophageal reflux disease (GERD), addresses a growing healthcare need among the 1 billion people worldwide who suffer from acid reflux. Unlike traditional treatment methods, which can lead to various complications, RefluxStop® aims to maintain the natural anatomical position of the lower esophageal sphincter, thereby minimizing side effects while effectively treating GERD.

During the Capital Markets Day, attendees will delve deeper into the strategies surrounding the U.S. launch and gain valuable insights into the businesses’ future direction. Participants will include RefluxStop® surgeons and patients, offering a comprehensive view of both clinical and patient perspectives. The agenda and speaker lineup are set to be disclosed as the event date approaches.

The event promises to be an enriching opportunity for investors to understand the growth trajectory of Implantica and to witness firsthand the exciting advancements in medical technology aimed at improving patient outcomes. Participants are encouraged to register ahead of time via email at [email protected].

About Implantica

Implantica is focused on revolutionizing healthcare by integrating sophisticated technologies into medical treatments. The RefluxStop® is one of their leading products, which is both FDA-approved and CE-marked, representing a significant clinical breakthrough in the treatment of GERD. The potential of RefluxStop® is backed by robust clinical data demonstrating its effectiveness and minimal risk when properly utilized.

Being listed on the Nasdaq First North Premier Growth Market, Implantica is dedicated to expanding its impact in the global healthcare market through continuous innovation and development of implantable technologies. The company’s future prospects include enhancing their product pipeline with a range of patented technologies, including a pioneering eHealth platform for remote monitoring and control of implants.

To learn more about Implantica and its innovative product line, visit Implantica's website.

Conclusion

As the healthcare landscape continues to evolve, Implantica stands at the forefront of medical technology with its commitment to enhancing patient care through advanced solutions like RefluxStop®. Investors and stakeholders alike are eagerly watching as the company prepares for its U.S. launch, setting the stage for what could be a transformative impact on the treatment of acid reflux.